Abstracts - faqs.org

Abstracts

Business, international

Search abstracts:
Abstracts » Business, international

Words of praise, and caution, for the humble aspirin

Article Abstract:

Approximately 6,000 physicians in Britain are testing the efficacy of aspirin to minimize heart problems, by taking an aspirin a day for the next few years. Aspirin may also be effective as a preventative for blood clots within arteries and other blood circulatory problems. A short history of aspirin and a few theories as to how it works to reduce fever, relieve minor pain, and act as an anti-inflammatory are discussed. A few warnings related to aspirin use are identified: people who have diabetes and individuals who take anticoagulant drugs should never take aspirin, children should not be given aspirin except under a doctor's care, and no one should exceed the recommended dosage printed on the aspirin packaging.

Author: O'Donnell, Michael
Publisher: Reed Business Information Ltd.
Publication Name: International Management
Subject: Business, international
ISSN: 0020-7888
Year: 1986
Heart diseases, Blood circulation, Great Britain

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Aspirin: a 'sensational' remedy for heart attacks

Article Abstract:

Research covering over 17,000 patients who had suffered heart attacks reveals that aspirin, even without injection of streptokinase, can reduce the likelihood of a patient dying by over 40%. Over 400 hospitals in Europe, North America, and Australasia were involved in the study, which was based at Oxford University in England. The debate over the best way to prevent and treat heart attacks comes at a time when genetic engineers have developed a new thrombolytic agent known as tissue plasminogen activator (t-PA). Conservative doctors have suggested that those who advocate t-PA use are overly affected by the novelty of the new drug.

Author: O'Donnell, Michael
Publisher: Reed Business Information Ltd.
Publication Name: International Management
Subject: Business, international
ISSN: 0020-7888
Year: 1988
Evaluation, Prevention, Heart attack, Tissue plasminogen activator, Fibrinolytic agents, Thrombolytic drugs, Streptokinase

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Unseen complications

Article Abstract:

Physicians recommend routine eye examinations should be undertaken after the age of 50 in order to ascertain whether there is any evidence of glaucoma. Glaucoma afflicts one out of every 50 Europeans over the age of 40. Glaucoma leads to a buildup of pressure in the eyeball which destroys the filaments of the nerves of the eye leading to a permanent loss of vision. The first stages of glaucoma produces no symptoms, thus the need for regular eye exams. If detected early, vision loss can be prevented through the use of eye drops.

Author: O'Donnell, Michael
Publisher: Reed Business Information Ltd.
Publication Name: International Management
Subject: Business, international
ISSN: 0020-7888
Year: 1991
Care and treatment, Eye, Glaucoma, column

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Usage, Aspirin
Similar abstracts:
  • Abstracts: For Sybase, employees and customers come first. Asia's Hewlett-Packard Watch. In the palm of Acer's hand
  • Abstracts: Rumors of rate reduction shake up equity markets. Count intangible assets for good of your financial health. Hong Kong investors may get active
  • Abstracts: Australia, New Zealand reach pact on single aviation market. Singapore ends Air India bid
  • Abstracts: Do source of mailing and monetary incentives matter in international industrial mail surveys? Brand values related to industrial products
  • Abstracts: Driving forces. Patent remedies. On the prevalence of madness in businessmen
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2018 Advameg, Inc.